7/7/2019 Bronte Capital: Valeant and Norma Provencio: Hmmm...


brontecapital.blogspot.com/2016/01/valeant-and-norma-provencio-hmmm.html 1/5


The sometimes eccentric views of John Hempton


Bronte Capital


Sunday, January 10, 2016


Valeant and Norma Provencio: Hmmm...
In December Bloomberg published an article observing that Norma Provencio (the head of the
Board's Audit Committee) had held a similar position in a company (Heartronics/Signalife) which had
been exposed as a major fraud. 
 
Mitchell Stein ­ the key executive at Heartronics/Signalife went to prison. The Valeant press release
(repeated in full below) states: 
 


Ms. Provencio has followed the criminal case against Mr. Stein and believes that the
matter was handled appropriately.


 
The same press release also absolves Norma Provencio from a long involvement in the fraud by
stating: 


With respect to her tenure at Signalife, Ms. Provencio served as a member of the Board
of Directors and chair of its Audit Committee from  July 2005 to June 2007.  She chose
not stand for re­election to the board of directors of Signalife.


In other words Ms Provencio was not there very long, certainly not involved since inception and she
thinks the criminal case was handled appropriately. 
 
Except that Norma Provencio was there from ear inception and was in business with Mitchell Stein
from the first involvement I can find from Mitchell Stein.  Here is a link for an annual report for Recom
Managed Services. That is the company that by reverse merger became Signalife/Heartronics. 
 
And that report makes clear that the original funding for the deals came from Norma Provencio and
Mitchell Stein. 
 


On May 15, 2003, we completed the first tranche of a private placement pursuant to
which we sold 82,667 units to Mr. Mitchell Stein, SJ Investments and Ms. Norma
Provencio at $3 per unit for cash amounting to $248,000. Each unit consisted of one
common share and one warrant. Each warrant is exercisable at $3 until May 14, 2004.
Upon exercise of the warrants each investor will receive one common share and an
additional warrant to purchase one common share $6 per share until November 15,
2004.


 
So Norma Provencio ­ chair of the Audit Committee of Valeant ­ was in business with the convicted
crook from the inception of the criminal business and over two years prior to what Valeant press­
releases as her involvement. 
 
Valeant elided that fact in their press release (repeated in full below). Whether Valeant PR elided that
fact deliberately matters. 
 
Either 
 
(a) Provencio misled Valeant as to the nature of her involvement with Mitchell Stein, the convicted
perpetrator of the Heartronics/Signalife fraud (and Valeant did not knowingly elide the truth in their
press release) or 
 
(b) Valeant is actively and deliberately misleading about the time that Ms Provencio was in business
with the convicted criminal.  
 
The second is unthinkable. Norma Provencio should resign from the Valeant board. 
 


For people who want to know - here is
the RSS feed for this blog...
 
http://feeds.feedburner.com/bronteca
pital


RSS feed


Enter your email address:


Subscribe


Delivered by FeedBurner


Get this blog by email


I find Americans sometimes do not get
a British or Australian sense of humor.
 
If something on this blog makes you
really angry I suggest you read Swift's
Modest Proposal... you will find the link
here.


A note on humor


Search


Search This Blog


April (3)


February (1)


January (1)


November (1)


October (2)


September (3)


August (4)


July (1)


May (1)


February (2)


January (1)


December (3)


Blog Archive


More  Create Blog   Sign In



http://brontecapital.blogspot.com/

http://www.bloomberg.com/news/articles/2015-12-15/valeant-s-audit-cop-held-similar-post-at-a-firm-felled-by-fraud

http://www.valeantnow.com/the-facts-on-norma-provencios-tenure-as-a-director-of-valeant-pharmaceuticals/

http://www.sec.gov/Archives/edgar/data/810365/000114420404007314/v03550_10ksba.htm

http://feeds.feedburner.com/brontecapital

http://www.feedburner.com/

http://art-bin.com/art/omodest.html

http://brontecapital.blogspot.com/2019/04/

http://brontecapital.blogspot.com/2019/02/

http://brontecapital.blogspot.com/2019/01/

http://brontecapital.blogspot.com/2018/11/

http://brontecapital.blogspot.com/2018/10/

http://brontecapital.blogspot.com/2018/09/

http://brontecapital.blogspot.com/2018/08/

http://brontecapital.blogspot.com/2018/07/

http://brontecapital.blogspot.com/2018/05/

http://brontecapital.blogspot.com/2018/02/

http://brontecapital.blogspot.com/2018/01/

http://brontecapital.blogspot.com/2017/12/

https://www.blogger.com/

https://www.blogger.com/home#create

https://www.blogger.com/
7/7/2019 Bronte Capital: Valeant and Norma Provencio: Hmmm...


brontecapital.blogspot.com/2016/01/valeant-and-norma-provencio-hmmm.html 2/5


 
 
 
John Hempton 
 
 
 
 
The Full Valeant release: 
 


 
 
 
Share this on:     Twitter     |     Facebook
 


December 15, 2015


Bloomberg News has published an article examining Norma Provencio’s tenure on the Board of
Directors of Signalife and Valeant. In connection with this inquiry, Valeant provided the following
information to Bloomberg News:


Ms. Provencio  was first elected, as a non-incumbent nominee, to Legacy Valeant’s board in 2007. 
More than 95% of the votes cast by shareholders with respect to her nomination were cast “for” Ms.
Provencio’s election to the Legacy Valeant Board.  In nominating Ms. Provencio, the Legacy Valeant
Board, thorough its Corporate Governance/Nominating Committee, a customary background check
and interview process was conducted.


Ms. Provencio was appointed chairperson of the Audit and Risk Committee of VPII (the current
company, as surviving company of the 2010 Biovail-Legacy Valeant merger) in 2011.  Ms. Provencio
served as the Chairperson of the Finance and Audit Committee of VPI from May 2008 until the Biovail
merger in September 2010.  So, in addition to her accomplished professional background and
qualifications, the Board had actual experience working with Ms. Provencio, as a director and as an
audit committee chair, and obviously felt comfortable with entrusting her with as the Chairperson of
VPII’s Audit and Risk Committee since 2011.


Ms. Provencio has many years of financial and industry experience that make her well qualified to
serve on Valeant’s Board. Ms. Provencio has been a certified public accountant since 1981 and
served as the audit partner on numerous public companies with complex accounting issues during
her public accounting career.  She has also lead numerous investigations for public and private
companies and has been the forensic accountant  for numerous special committees during her
professional career.


The Board has determined that Ms. Provencio’s many years of sophisticated financial and industry
specific experience at Provencio Advisory Services, Inc., KPMG LLP and Arthur Andersen, her service
on the board and finance and audit committee of VPI, her wealth of knowledge in dealing with
financial and accounting matters and the depth and breadth of her exposure to complex financial
issues qualify her to be a member of the Board and the committees on which she sits.


Ms. Provencio’s directorship with Signalife was disclosed in Valeant’s proxy statement, in compliance
with applicable SEC rules. Prior to 2010, the proxy rules required disclosure of then-current public
company directorships.  Accordingly, Valeant’s 2007 proxy disclosed Ms. Provencio’s directorship with
Signalife.  Beginning in 2010, the proxy disclosure rules introduced a 5-year look back, and
accordingly, Valeant’s proxy statements filed in 2010, 2011, 2012 and 2013 disclosed Ms. Provencio’s
previous directorship with Signalife.


The ad hoc committee was appointed by the Board of Directors to review allegations related to the
company’s business relationship with Philidor and related matters, and consists entirely of
independent directors.


The Facts on Norma Provencio’s Tenure as a
Director of Valeant Pharmaceuticals


November (1)


October (1)


August (2)


July (2)


June (2)


May (3)


April (2)


February (1)


January (3)


December (6)


November (4)


October (4)


September (6)


August (1)


July (5)


June (3)


May (3)


April (2)


March (10)


February (3)


January (3)


December (4)


November (8)


October (10)


September (4)


August (3)


July (2)


June (1)


May (5)


April (6)


March (5)


February (6)


January (9)


December (3)


November (4)


October (8)


September (8)


August (12)


July (5)


June (10)


May (7)



http://twitter.com/share?text=The+Facts+on+Norma+Provencio%E2%80%99s+Tenure+as+a+Director+of+Valeant+Pharmaceuticals&url=http://www.valeantnow.com/the-facts-on-norma-provencios-tenure-as-a-director-of-valeant-pharmaceuticals/

http://www.facebook.com/sharer.php?u=http://www.valeantnow.com/the-facts-on-norma-provencios-tenure-as-a-director-of-valeant-pharmaceuticals/&t=The+Facts+on+Norma+Provencio%E2%80%99s+Tenure+as+a+Director+of+Valeant+Pharmaceuticals

http://brontecapital.blogspot.com/2017/11/

http://brontecapital.blogspot.com/2017/10/

http://brontecapital.blogspot.com/2017/08/

http://brontecapital.blogspot.com/2017/07/

http://brontecapital.blogspot.com/2017/06/

http://brontecapital.blogspot.com/2017/05/

http://brontecapital.blogspot.com/2017/04/

http://brontecapital.blogspot.com/2017/02/

http://brontecapital.blogspot.com/2017/01/

http://brontecapital.blogspot.com/2016/12/

http://brontecapital.blogspot.com/2016/11/

http://brontecapital.blogspot.com/2016/10/

http://brontecapital.blogspot.com/2016/09/

http://brontecapital.blogspot.com/2016/08/

http://brontecapital.blogspot.com/2016/07/

http://brontecapital.blogspot.com/2016/06/

http://brontecapital.blogspot.com/2016/05/

http://brontecapital.blogspot.com/2016/04/

http://brontecapital.blogspot.com/2016/03/

http://brontecapital.blogspot.com/2016/02/

http://brontecapital.blogspot.com/2016/01/

http://brontecapital.blogspot.com/2015/12/

http://brontecapital.blogspot.com/2015/11/

http://brontecapital.blogspot.com/2015/10/

http://brontecapital.blogspot.com/2015/09/

http://brontecapital.blogspot.com/2015/08/

http://brontecapital.blogspot.com/2015/07/

http://brontecapital.blogspot.com/2015/06/

http://brontecapital.blogspot.com/2015/05/

http://brontecapital.blogspot.com/2015/04/

http://brontecapital.blogspot.com/2015/03/

http://brontecapital.blogspot.com/2015/02/

http://brontecapital.blogspot.com/2015/01/

http://brontecapital.blogspot.com/2014/12/

http://brontecapital.blogspot.com/2014/11/

http://brontecapital.blogspot.com/2014/10/

http://brontecapital.blogspot.com/2014/09/

http://brontecapital.blogspot.com/2014/08/

http://brontecapital.blogspot.com/2014/07/

http://brontecapital.blogspot.com/2014/06/

http://brontecapital.blogspot.com/2014/05/
7/7/2019 Bronte Capital: Valeant and Norma Provencio: Hmmm...


brontecapital.blogspot.com/2016/01/valeant-and-norma-provencio-hmmm.html 3/5


Posted by John Hempton at 10:04 PM   


The votes appointing Ms. Provencio to the ad hoc committee and as chairperson to of the ARC were
unanimous. And at each election of directors since Ms. Provencio was appointed to the Legacy
Valeant board in 2007, she received the overwhelming support of shareholders as demonstrated by
the shareholder vote.


Mike Pearson commented, “Since I have known Norma Provencio, she has acted with integrity and
displayed sound business judgment, and I believe that she is exceptionally well qualified to lead our
Board’s Audit & Risk Committee.”


***


With respect to her tenure at Signalife, Ms. Provencio served as a member of the Board of Directors
and chair of its Audit Committee from  July 2005 to June 2007.  She chose not stand for re-election
to the board of directors of Signalife.


The only financial reporting matter that Ms. Provencio is specifically aware of that overlapped with her
tenure on the Signalife board is a sale in September 2006 of $190,170 that was alleged to have not
been a legitimate sale.  With respect to that specific matter, the SEC complaint states that it was
concealed from that company’s CFO, auditors, outside counsel and other officers.


Signalife engaged outside CPA firms to perform its accounting functions during Ms. Provencio’s tenure
on the board.  The CPA firms included Robert C. Scherne, CPA, PC  and Pickard & Green.  Both CPA
firms provided accounting and other management consulting services for small companies, including
preparing required SEC filings for public companies.


Ms. Provencio has followed the criminal case against Mr. Stein and believes that the matter was
handled appropriately.


 
Post script: The original reverse merger was in the second half of 2002 as per the annual report
described above. Mitchell Stein's name does not appear before 2003 and appears in precisely the
same deal as Norma Provencio.


